<p>Cadila Healthcare on Wednesday said its subsidiary has received approval from the US health regulator to market Macitentan tablets, used to treat high blood pressure, in the American market.</p>.<p>Zydus Worldwide DMCC, a wholly-owned subsidiary of the company, has received tentative approval from the US Food and Drug Administration (USFDA) to market Macitentan tablets, Cadila Healthcare said in a statement.</p>.<p>The tablets are indicated for the treatment of pulmonary arterial hypertension and will be manufactured at Vapi-based CMO Umedica Laboratories, it added.</p>.<p>The Zydus Cadila group now has 287 approvals and has so far filed over 386 abbreviated new drug applications since the commencement of the filing process in 2003-04, the company said.</p>
<p>Cadila Healthcare on Wednesday said its subsidiary has received approval from the US health regulator to market Macitentan tablets, used to treat high blood pressure, in the American market.</p>.<p>Zydus Worldwide DMCC, a wholly-owned subsidiary of the company, has received tentative approval from the US Food and Drug Administration (USFDA) to market Macitentan tablets, Cadila Healthcare said in a statement.</p>.<p>The tablets are indicated for the treatment of pulmonary arterial hypertension and will be manufactured at Vapi-based CMO Umedica Laboratories, it added.</p>.<p>The Zydus Cadila group now has 287 approvals and has so far filed over 386 abbreviated new drug applications since the commencement of the filing process in 2003-04, the company said.</p>